W. L. GORE & ASSOCIATES, INC. GORE® VIABAHN® VBX BALLOON EXPANDABLE ENDOPROSTHESIS; ILIAC COVERED STENT, ARTERIAL
|
Back to Search Results |
|
Catalog Number BXA095902A |
Device Problem
Fracture (1260)
|
Patient Problem
No Clinical Signs, Symptoms or Conditions (4582)
|
Event Date 12/22/2022 |
Event Type
malfunction
|
Event Description
|
The following information was from a study: on may 2021, a patient underwent an abdominal aortic aneurysm procedure.A gore® viabahn® vbx balloon expandable endoprosthesis was implanted as a side branch within the celiac artery, most proximal within the portal.During an interim patient visit on (b)(6) 2022, a wire fracture was observed on the celiac artery side branch component using a ct imaging only.The fractures appear to be in the 3rd and 4th stent rows from the distal end of the side branch component within the celiac artery.It was noted a very high quality ct scan with 0.60 slice thickness and 0.40 spacing was used to make this definitive observation.It is was not specified it patient experienced any adverse consequences from the observed fracture.It is unknown if the fracture required an intervention.On (b)(6) 2023, the patient expired due to chronic obstructive pulmonary disease.As reported, the patient's death was unrelated to the gore devices implanted during the aaa procedure.
|
|
Manufacturer Narrative
|
Cbas® heparin surface incorporates carmeda heparin manufactured from heparin sodium api, which is covalently bound to the device surface and is essentially non-eluting.H3: device remains implanted; therefore, direct product analysis was not possible.H6 - code c19: review of device manufacturing record history confirmed device met pre-release specifications.W.L.Gore & associates, inc.(gore) is submitting this report to comply with 21 c.F.R.Part 803, the medical device reporting regulation.This report is based upon information obtained by gore, which the company may not have been able to fully investigate or verify prior to the date the report was required by the fda.Blank fields present on this report include required fields and fields determined to be not applicable.Blank required fields indicate that the information was not provided, was deemed unavailable or was not applicable.This report does not constitute an admission or a conclusion by fda, gore, or its associates that the device, gore or its associates caused or contributed to the event described in the report.In particular, this report does not constitute a legal admission by anyone that the product described in this report has any defects or has malfunctioned, as defined from a legal standpoint.These words are included in the report and are fixed items for selection created by the fda, to categorize the type of event solely for the purpose of reporting pursuant to part 803.This statement should be included with any information or report disclosed to the public under the freedom of information act.
|
|
Manufacturer Narrative
|
The imaging evaluation performed by a clinical imaging specialist showed the following: two post-implantation time-points used for evaluation dated (b)(6) 2021 and (b)(6) 2022.On the(b)(6) 2021 image set, cannot confirm wire fracture(s) or stent row disruption in the distal portion of the stent in the celiac artery.On (b)(6) 2022, wire fracture(s) are confirmed within the distal portion of the vbx device in the celiac artery.The fracture(s) appear to be in the 3rd and 4th stent rows from the distal end of the device in the celiac artery.
|
|
Search Alerts/Recalls
|
|
|